, European Monitoring Centre for Drugs and Drug Addiction, Europol. Methamphetamine: a European Union perspective in the global context, EMCDDA | interactive source table, vol.1, 2009.

F. Romanelli and K. M. Smith, Clinical effects and management of methamphetamine abuse, Pharmacotherapy. août, vol.26, issue.8, pp.1148-56, 2006.

M. D. Anglin, C. Burke, B. Perrochet, E. Stamper, and S. Dawud-noursi, History of the Methamphetamine Problem, J Psychoactive Drugs. 1 juin, vol.32, issue.2, pp.137-178, 2000.

F. Pomès, Les junkies d'Hitler : La Pervitine (méthamphétamine) dans l'Allemagne Nazie et la Wehrmacht. Diffusé sur RMC découverte et LCP

D. Sur,

B. K. Logan, Amphetamines: An Update on Forensic Issues, J Anal Toxicol. 1 juill, vol.25, issue.5, pp.400-404, 2001.

M. Hydrochloride, MARTINDALE -Complete Drug Ref, p.4

, Terminology and information on drugs. Vienna: Publishing and Library Section, United Nations O ce, 2016.

L. Karila, A. Petit, O. Cottencin, and M. Reynaud, Dépendance à la méthamphétamine : de nombreuses conséquences et complications, Presse Médicale. déc, vol.39, issue.12, pp.1246-53, 2010.

T. J. Abbruscato and P. C. Trippier, DARK Classics in chemical neuroscience: methamphetamine, ACS Chem Neurosci. 6 avr, vol.9, issue.10, pp.2373-2381, 2018.

, Exploring methamphetamine trends in Europe, EMCDDA Papers, Publications Office of the European Union, EMCDDA, 2014.

A. Allen and T. S. Cantrell, Synthetic reductions in clandestine amphetamine and methamphetamine laboratories: A review, Forensic Sci Int. août, vol.42, issue.3, pp.183-99, 1989.

A. C. Allen and W. O. Kiser, Methamphetamine from ephedrine: I. chloroephedrines and aziridines, J Forensic Sci. 1 juill, vol.32, issue.4, pp.953-62, 1987.

V. Kunalan, N. Daéid, N. Kerr, W. J. Buchanan, H. Mcpherson et al., Characterization of Route Specific Impurities Found in Methamphetamine Synthesized by the Leuckart and Reductive Amination Methods, Anal Chem. sept, vol.81, issue.17, pp.7342-7350, 2009.

C. C. Cruickshank and K. R. Dyer, A review of the clinical pharmacology of methamphetamine, Addiction. Fev, vol.104, issue.7, pp.1085-99, 2009.

K. E. Courtney and L. A. Ray, Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature, Drug Alcohol Depend, vol.1, issue.0, pp.11-21, 2015.

D. E. Rusyniak, Neurologic manifestations of chronic methamphetamine abuse, Neurol Clin. août, vol.29, issue.3, pp.641-55, 2011.

, United Nations Publications. World Drug Report, 2017.

E. Unodc, Methamphetamine continues to dominate synthetic drug markets, Global SMART Update, vol.20, 2018.

, European Monitoring Centre for Drugs and Drug Addiction, éditeur. Problem amphetamine and methamphetamine use in Europe. Luxembourg: Publ. Office of the European Union, vol.35, 2010.

B. D. Homer, T. M. Solomon, R. W. Moeller, A. Mascia, L. Deraleau et al., Methamphetamine abuse and impairment of social functioning: A review of the underlying neurophysiological causes and behavioral implications, Psychol Bull, vol.134, issue.2, pp.301-311, 2008.

J. Harro, Neuropsychiatric adverse effects of amphetamine and methamphetamine, International Review of Neurobiology, pp.179-204, 2015.

D. Sulzer, M. S. Sonders, N. W. Poulsen, and A. Galli, Mechanisms of neurotransmitter release by amphetamines: A review, Prog Neurobiol. avr, vol.75, issue.6, pp.406-439, 2005.

D. Sulzer, How Addictive Drugs Disrupt Presynaptic Dopamine Neurotransmission, Neuron. Fev, vol.69, issue.4, pp.628-677, 2011.

E. V. Mosharov, K. E. Larsen, E. Kanter, K. A. Phillips, K. Wilson et al., Interplay between cytosolic dopamine, calcium, and ?-synuclein causes selective death of substantia nigra neurons, Neuron. 30 avr, vol.62, issue.2, pp.218-247, 2009.

K. Wimalasena, Vesicular monoamine transporters: Structure-function, pharmacology, and medicinal chemistry, Med Res Rev. juill, vol.31, issue.4, pp.483-519, 2011.

S. J. Kish, Pharmacologic mechanisms of crystal meth, Can Med Assoc J. 17 juin, vol.178, issue.13, pp.1679-82, 2008.

S. Vergo, J. L. Johansen, M. Leist, and J. Lotharius, Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels, Brain Res. déc, vol.1185, pp.18-32, 2007.

U. D. Mccann, D. F. Wong, F. Yokoi, V. Villemagne, R. F. Dannals et al., Reduced Striatal Dopamine Transporter Density in Abstinent Methamphetamine and Methcathinone Users: Evidence from Positron Emission Tomography Studies with [11C]WIN-35,428, J Neurosci, vol.18, issue.20, pp.8417-8439, 1998.

C. W. Berridge and B. D. Waterhouse, The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes, Brain Res Rev. avr, vol.42, issue.1, pp.33-84, 2003.

J. Hornung, Berridge CW. Neural substrates of psychostimulant-induced arousal, Neuropsychopharmacology, vol.26, issue.4, pp.2332-2372, 2003.

D. S. Bell, The experimental reproduction of amphetamine psychosis, Arch Gen Psychiatry. 1 juill, vol.29, issue.1, pp.35-40, 1973.

H. Inoue, N. Ikeda, K. Kudo, T. Ishida, M. Terada et al., Methamphetamine-related sudden death with a concentration which was of a 'toxic level', Leg Med. mai, vol.8, issue.3, pp.150-155, 2006.

M. Ago, K. Ago, K. Hara, S. Kashimura, and M. Ogata, Toxicological and histopathological analysis of a patient who died nine days after a single intravenous dose of methamphetamine: A case report, Leg Med. juill, vol.8, issue.4, pp.235-244, 2006.

H. J. Smith, A. Roche, M. F. Jagusch, and P. B. Herdson, Cardiomyopathy associated with amphetamine administration, Am Heart J. juin, vol.91, issue.6, pp.792-799, 1976.

E. R. Olsen, Intracranial hemorrhage and amphetamine usage: review of the effects of amphetamines on the central nervous system, Angiology. juill, vol.28, issue.7, pp.464-71, 1977.

S. Shibata, K. Mori, I. Sekine, and H. Suyama, An autopsy case of subarachnoid and intracerebral hemorrhage and necrotizing angitis associated with methamphetamine abuse. No Shinkei, vol.40, pp.1089-94, 1988.

A. Ishigami, I. Tokunaga, T. Gotohda, and S. Kubo, Immunohistochemical study of myoglobin and oxidative injury-related markers in the kidney of methamphetamine abusers, Leg Med. mars, vol.5, issue.1, pp.42-50, 2003.

T. Kojima, U. I. Yashiki, M. Noda, J. Sakap, K. Yamamotcr et al., A fatal methamphetamine poisoning associated with hyperpyrexia, Forensic Sci Int, vol.24, pp.87-93, 1984.

S. C. Jordan and F. Hampson, Amphetamine Poisoning Associated with Hyperpyrexia, Br Med J. 17 sept, vol.2, issue.5202, pp.844-844, 1960.

H. Kalant and O. Josseau, Death in amphetamine users: causes and rates, CMA J. Fev, vol.112, pp.299-304, 1975.

B. K. Logan, C. L. Fligner, and T. Haddix, Cause and manner of death in fatalities involving methamphetamine, J Forensic Sci. janv, vol.43, issue.1, pp.28-34, 1998.

C. Kuo, C. Chen, and . Commentary-on-darke, What is the real distribution of methamphetamine-related causes of death ?, Addiction. déc, vol.112, issue.12, pp.2202-2207, 2017.

D. Hamamoto and N. Rhodus, Methamphetamine abuse and dentistry, Oral Dis. janv, vol.15, issue.1, pp.27-37, 2009.

S. D. Turnipseed, J. R. Richards, J. D. Kirk, D. B. Diercks, and E. A. Amsterdam, Frequency of acute coronary syndrome in patients presenting to the Emergency Department with chest pain after methamphetamine use, J Emerg Med. mai, vol.24, issue.4, pp.369-73, 2003.

E. D. Paratz, N. J. Cunningham, and A. I. Macisaac, The cardiac complications of methamphetamines, Heart Lung Circ. avr, vol.25, issue.4, pp.325-357, 2016.

S. Kaye, R. Mcketin, J. Duflou, and S. Darke, Methamphetamine and cardiovascular pathology: a review of the evidence, Addiction. août, vol.102, issue.8, pp.1204-1215, 2007.

T. Segawa, Y. Arita, N. Ogasawara, and S. Hasegawa, Hypertensive heart disease associated with methamphetamine abuse, J Cardiol Cases. févr, vol.19, issue.2, pp.47-50, 2019.

S. M. Mcgee, D. N. Mcgee, and M. B. Mcgee, Spontaneous intracerebral hemorrhage related to methamphetamine abuse: autopsy findings and clinical correlation, Am J Forensic Med Pathol. déc, vol.25, issue.4, pp.334-341, 2004.

C. I. Swalwell and G. G. Davis, Methamphetamine as a risk factor for acute aortic dissection, J Forensic Sci. janv, vol.44, issue.1, pp.23-29, 1999.

E. Wako, D. Ledoux, L. Mitsumori, and G. S. Aldea, The emerging epidemic of methamphetamineinduced aortic dissections, J Card Surg. sept, vol.22, issue.5, pp.390-393, 2007.

R. L. Ramirez, V. Perez, and R. T. Zamanian, Methamphetamine and the risk of pulmonary arterial hypertension, Curr Opin Pulm Med. sept, vol.24, issue.5, pp.416-440, 2018.

R. T. Zamanian, H. Hedlin, P. Greuenwald, D. M. Wilson, J. I. Segal et al., Features and Outcomes of Methamphetamine-associated Pulmonary Arterial Hypertension, Am J Respir Crit Care Med. 15 mars, vol.197, issue.6, pp.788-800, 2018.

K. M. Chin, R. N. Channick, and L. J. Rubin, Is methamphetamine use associated with idiopathic pulmonary arterial hypertension ?, Chest. déc, vol.130, issue.6, pp.1657-63, 2006.

S. Schürer, K. Klingel, M. Sandri, N. Majunke, C. Besler et al., Clinical characteristics, histopathological features, and clinical outcome of methamphetamine-associated cardiomyopathy, JACC Heart Fail. juin, vol.5, issue.6, pp.435-480, 2017.

K. Yeo, M. Wijetunga, H. Ito, J. T. Efird, K. Tay et al., The association of methamphetamine use and cardiomyopathy in young patients, Am J Med. févr, vol.120, issue.2, pp.165-71, 2007.

A. Pabst, J. Castillo-duque, A. Mayer, M. Klinghuber, and R. Werkmeister, Meth Mouth-A Growing Epidemic in Dentistry? Dent J, vol.5, p.29, 2017.

C. De-carolis, B. Ga, L. Mancinelli, S. Pagano, and S. Eramo, Methamphetamine abuse and meth mouth in Europe, Med Oral Patol Oral Cir Bucal. 1 mai, vol.20, issue.2, p.1491, 2005.

T. Ye, D. Sun, G. Dong, G. Xu, L. Wang et al., The effect of methamphetamine abuse on dental caries and periodontal diseases in an Eastern China city, BMC Oral Health. déc, vol.18, issue.1, pp.1-6, 2018.

T. S. Saini, P. C. Edwards, N. S. Kimmes, L. R. Carroll, J. W. Shaner et al., Etiology of Xerostomia and Dental Caries among Methamphetamine Abusers. Oral Health Prev Dent, vol.3, pp.189-95, 2005.

D. Klasser, Methamphetamine and its impact on dental care, J Can Dent Assoc, vol.71, issue.10, pp.759-62, 2005.

. Trismus, m%C3%A9decine)&oldid=155169031 65. Bruxisme. In: Wikipédia [Internet, 2018.

J. Rustemeyer, A. Melenberg, K. Junker, and A. Sari-rieger, Osteonecrosis of the maxilla related to longstanding methamphetamine abuse: a possible new aspect in the etiology of osteonecrosis of the jaw, Oral Maxillofac Surg. juin, vol.18, issue.2, pp.237-278, 2014.

M. Ferrucci, L. Pasquali, A. Paparelli, S. Ruggieri, and F. Fornai, Pathways of Methamphetamine Toxicity

, Ann N Y Acad Sci, vol.1139, issue.1, pp.177-85, 2008.

V. Villemagne, J. Yuan, D. F. Wong, R. F. Dannals, G. Hatzidimitriou et al., Brain Dopamine Neurotoxicity in Baboons Treated with Doses of Methamphetamine Comparable to Those Recreationally Abused by Humans: Evidence from [11C]WIN-35,428 Positron Emission Tomography Studies and Direct In Vitro Determinations, J Neurosci. 1 janv, vol.18, issue.1, pp.419-446, 1998.

D. C. Harvey, G. Lacan, S. P. Tanious, and W. P. Melega, Recovery from methamphetamine induced longterm nigrostriatal dopaminergic deficits without substantia nigra cell loss, Brain Res. juill, vol.871, issue.2, pp.259-70, 2000.

J. Rumpf, J. Albers, C. Fricke, W. Mueller, and J. Classen, Structural abnormality of substantia nigra induced by methamphetamine abuse: Abnormality of SN Induced by Methamphetamine, Mov Disord. déc, vol.32, issue.12, pp.1784-1792, 2017.

E. D. London, M. Kohno, A. M. Morales, and M. E. Ballard, Chronic methamphetamine abuse and corticostriatal deficits revealed by neuroimaging, Brain Res. 2 déc, vol.1628, pp.174-85, 2015.

J. Tassin, Neurobiologie de l'addiction : proposition d'un nouveau concept, Inf Psychiatr. Fev, vol.83, issue.2, pp.91-98, 2007.

R. Mcketin, J. Mclaren, D. I. Lubman, and L. Hides, The prevalence of psychotic symptoms among methamphetamine users. Addiction, vol.101, pp.1473-1481, 2006.

. Arlington, Diagnostic And Statistical Manual of Mental Disorders : DSM-5. VA, 2013.

W. Schultz, P. Dayan, and P. R. Montague, A Neural Substrate of Prediction and Reward, Science. 14 mars, vol.275, issue.5306, pp.1593-1602, 1997.

D. Chiara, G. Imperato, and A. , Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats, Proc Natl Acad Sci U A. 1 juill, vol.85, issue.14, pp.5274-5282, 1988.

A. Moszczynska, P. Fitzmaurice, L. Ang, K. S. Kalasinsky, G. A. Schmunk et al., Why is parkinsonism not a feature of human methamphetamine users? Brain, Fev, vol.127, issue.2, pp.363-70, 2004.

C. Drouin, L. Darracq, F. Trovero, G. Blanc, J. Glowinski et al., Alpha1b-adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates, J Neurosci Off J Soc Neurosci. 1 avr, vol.22, issue.7, pp.2873-84, 2002.

A. Auclair, C. Drouin, S. Cotecchia, J. Glowinski, and J. Tassin, 5-HT2A and ?1b-adrenergic receptors entirely mediate dopamine release, locomotor response and behavioural sensitization to opiates and psychostimulants: 5-HT2A and ?1b-AR mediate behavioural sensitization, Eur J Neurosci. 2 déc, vol.20, issue.11, pp.3073-84, 2004.

L. Darracq, G. Blanc, J. Glowinski, and J. Tassin, Importance of the noradrenaline-dopamine coupling in the locomotor activating effects of d-amphetamine, J Neurosci. 1 avr, vol.18, issue.7, 1998.

D. Sur, MÉTAMPHÉTAMINES [Desoxyn® (USA), Méthédrine® (ANG), Pervitin®(ALL), Tonédron® (FRA)

V. Dictionnaire, , 1972.

, Precursors and chemicals frequently used in the illicit manufacture of narcotic drugs and psychotropic substances, United Nations Office, 2017.

J. K. Cunningham and L. Liu, Impacts of federal ephedrine and pseudoephedrine regulations on methamphetamine-related hospital admissions, Addiction. sept, vol.98, issue.9, pp.1229-1266, 2003.

A. Autorisation--minigraphie and S. ,

. Ansm, Autorisation -Minigraphie HUMEX Rhinite Allergique

D. Sur, 88. AFSSAPS. Commission nationale des stupéfiants et des psychotropes. Compte-rendu de la 79ième réunion du 17 avril, vol.18, 2008.

P. Griffiths, V. Mravcik, D. Lopez, and D. Klempova, Quite a lot of smoke but very limited fire -the use of methamphetamine in Europe, Drug Alcohol Rev. mai, vol.27, issue.3, pp.236-278, 2008.

E. Emcdda, Perspectives on drugs, Synthetic drug production, 2013.

, Illicit manufacture. Number of clandestine laboratories detected, 2011.

, Observatoire européen des drogues et des toxicomanies, editor. Rapport européen sur les drogues 2018: Tendances et évolutions. Office des publications de l'Union européenne, p.96, 2018.

, United Nations Publications. World Drug Report, 2018.

J. G. Bramness, M. J. Reid, K. F. Solvik, and V. Vindenes, Recent trends in the availability and use of amphetamine and methamphetamine in Norway, Forensic Sci Int. janv, vol.246, pp.92-99, 2015.

S. H. Lim, M. Akbar, J. A. Wickersham, A. Kamarulzaman, and F. L. Altice, The management of methamphetamine use in sexual settings among men who have sex with men in Malaysia, Int J Drug Policy. mai, vol.55, pp.256-62, 2018.

P. N. Halkitis, Longitudinal investigation of methamphetamine use among gay and bisexual men in New York city: findings from project BUMPS, J Urban Health Bull N Y Acad Med. 28 févr, vol.82, issue.1, pp.18-25, 2005.

T. Vu, N. T. Maher, L. Zablotska, and I. , Amphetamine-type stimulants and HIV infection among men who have sex with men: implications on HIV research and prevention from a systematic review and meta-analysis, J Int AIDS Soc. Fev, vol.18, issue.1, p.19273, 2015.

F. Chiadmi and J. Schlatter, Crystal meth : une forme de méthamphétamine, Presse Médicale. janv, vol.38, issue.1, pp.63-70, 2009.

G. Bolding, G. Hart, L. Sherr, and J. Elford, Use of crystal methamphetamine among gay men in London. Addiction, vol.101, pp.1622-1652, 2006.

A. , Risques liés à la pratique du ChemSex, 2018.

E. Emcdda, Perspectives on drugs, Health and social responses for methamphetamine users, 2014.

R. Mcketin, J. Ross, E. Kelly, A. Baker, N. Lee et al., Characteristics and harms associated with injecting versus smoking methamphetamine among methamphetamine treatment entrants, Drug Alcohol Rev. mai, vol.27, issue.3, pp.277-85, 2008.

. Serment-de-galien-je-jure, en présence des maîtres de la Faculté, des conseillers de l'ordre des Pharmaciens et de mes condisciples : D'honorer ceux qui m'ont instruit(e) dans les préceptes de mon art et de leur témoigner ma reconnaissance en restant fidèle à leur enseignement

, intérêt de la santé publique, ma profession avec conscience et de respecter non seulement la législation en vigueur, mais aussi les règles de l'honneur

, De ne jamais oublier ma responsabilité et mes devoirs envers le malade et sa dignité humaine

, En aucun cas, je ne consentirai à utiliser mes connaissances et mon état pour corrompre les moeurs et favoriser des actes criminels

, Que les hommes m'accordent leur estime si je suis fidèle à mes promesses

, Que je sois couvert(e) d'opprobre et méprisé(e) de mes confrères si j'y manque